Back to Search
Start Over
Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma
- Source :
- Human Pathology. 68:87-91
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alterations in the RAS oncogene family accumulate during the progression of SBT to invasive low-grade serous carcinoma (LGSC) remains largely unknown. Although mutations of KRAS and BRAF occur at a very early stage of progression, even preceding the development of SBT, additional driving events, such as NRAS mutations, have been postulated to facilitate progression. In this study, we analyzed NRAS exon 3 mutational status in 98 cases that were diagnosed with SBT/atypical proliferative serous tumor, noninvasive LGSC, or invasive LGSC. Of the latter, NRAS Q61R (CAA to CGA) mutations were detected in only 2 of 56 (3.6%) cases. The same mutation was not detected in any of the SBTs (atypical proliferative serous tumors) or noninvasive LGSCs. Mutational analysis for hotspots in KRAS and BRAF demonstrated a wild-type pattern of KRAS and BRAF in one of the NRAS-mutated cases. Interestingly, another LGSC case with NRAS mutation harbored a concurrent BRAF V600L mutation. These findings indicate that, although recurrent NRAS mutations are present, their low prevalence indicates that NRAS plays a limited role in the development of LGSC. Further studies to identify other oncogenic events that drive LGSC progression are warranted.
- Subjects :
- Adult
Proto-Oncogene Proteins B-raf
0301 basic medicine
Neuroblastoma RAS viral oncogene homolog
endocrine system diseases
Serous carcinoma
Denmark
DNA Mutational Analysis
medicine.disease_cause
Article
GTP Phosphohydrolases
Pathology and Forensic Medicine
Young Adult
03 medical and health sciences
Exon
0302 clinical medicine
Mutation Rate
Biomarkers, Tumor
medicine
Humans
Genetic Predisposition to Disease
Neoplasm Invasiveness
neoplasms
Aged
Cell Proliferation
Neoplasm Staging
Aged, 80 and over
Ovarian Neoplasms
Mutation
Oncogene
business.industry
Carcinoma
Membrane Proteins
Middle Aged
medicine.disease
digestive system diseases
Serous fluid
Phenotype
030104 developmental biology
030220 oncology & carcinogenesis
Baltimore
Cancer research
Female
KRAS
Neoplasm Grading
Neoplasms, Cystic, Mucinous, and Serous
Ovarian cancer
business
Subjects
Details
- ISSN :
- 00468177
- Volume :
- 68
- Database :
- OpenAIRE
- Journal :
- Human Pathology
- Accession number :
- edsair.doi.dedup.....a4772f71fdc41c1781cf772112ecbb7e